Related Experiment Video
Updated: Jun 22, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Staging of transitional cell carcinoma: Has anything changed?
1Department of Uro-oncology, Asian Institute of Oncology, SL Raheja Hospital, Mahim West, Mumbai - 400 016, India.
Objective:
This article is a systematic review of various changes in the evolution of the contemporary clinico-pathological staging of transitional cell carcinoma (TCC).
Materials And Methods:
A thorough search of the literature was done by Medline and other internet references.
Results:
Accurate staging of TCC is necessary for designing optimal therapy in clinical practice. Further, the current emphasis on bladder conservation and improved long-term disease free survival (DFS) necessitates minimal errors in staging and it's predictability towards recurrence and progression. Traditionally, the staging of TCC revolves around clinical and pathological findings. The staging has evolved through the understanding of various clinico- pathological factors like tumor appearance, number, size, grade, depth of invasion, muscle substratification, lymphovascular invasion and has reached the standard TNM classification. Cystoscopy and transurethral resection still remain the mainstay of staging and noninvasive imaging techniques have further enhanced the accuracy.
Conclusion:
The TNM classification for bladder cancer is currently the gold standard for TCC.
